CLINICAL_TRIALS
trial_result
· 2015-07-02
Clinical Trial Update: A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108) [Phase 3]
Summary
Results from a Phase 3, two-part 26-week study evaluating Etoricoxib for Ankylosing Spondylitis have been completed and posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Organon and Co | Conditions: Spondylitis, Ankylosing | Phase 3 | Status: COMPLETED | Results posted: 2015-07-02